NASDAQ: PHVSPharvaris Nv Stock
$34.01+0.71 (+2.13%)
Updated Jun 26, 2026
PHVS Price
$34.01
Fair Value Price
$5.62
Market Cap
$2.22B
52 Week Low
$16.72
52 Week High
$35.33
P/E
-10.55x
P/B
8x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$193.75M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.1
Operating Cash Flow
-$169M
Beta
0.53
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
PHVS Overview
Pharvaris N.V. is developing therapies for rare diseases. Its pipeline includes PHA121, PHVS416, PHVS719, all to treat hereditary angioedema. Pharvaris N.V was incorporated in 2015 and is headquartered in Leiden, the Netherlands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PHVS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important PHVS news, forecast changes, insider trades & much more!
PHVS News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PHVS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PHVS ($34.01) is overvalued by 505.33% relative to our estimate of its Fair Value price of $5.62 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
PHVS ($34.01) is not significantly undervalued (505.33%) relative to our estimate of its Fair Value price of $5.62 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
PHVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more PHVS due diligence checks available for Premium users.
Valuation
PHVS fair value
Fair Value of PHVS stock based on Discounted Cash Flow (DCF)
Price
$34.01
Fair Value
$5.62
Overvalued by
505.33%
PHVS ($34.01) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
PHVS ($34.01) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
PHVS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
PHVS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.55x
Industry
16.27x
Market
12.39x
PHVS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8x
Industry
5.34x
PHVS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PHVS's financial health
Profit margin
Revenue
$0.0
Net Income
-$45.1M
Profit Margin
0%
PHVS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$298.6M
Liabilities
$27.0M
Debt to equity
0.1
PHVS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PHVS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$56.1M
Investing
-$59.9k
Financing
-$70.7k
PHVS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PHVS vs Biotech Stocks
Pharvaris Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.